Abstract |
Sixty-six patients with seasonal allergic rhinitis due to birch pollens, participated in an efficacy evaluation of topically applied, nasal and ocular, levocabastine, a highly selective H1 antagonist. A single blind comparison was performed between nasal levocabastine and flunisolide, a topical glucocorticoid preparation. Ocular levocabastine was compared with topical naphazoline/ antazoline eye drops. Nasal and ocular symptom scores were recorded during a 31-day period. Pollen counts of birch pollens were done simultaneously. A global assessment of treatment efficacy was also made. In the comparison between the ocular treatments a significantly higher number of patients cited levocabastine excellent--it also had the advantage of fewer daily administrations. For nasal symptom scores the topical glucocorticosteroid therapy was in favour by number of sneezes. As for side effects, 44% of the patients complained of local irritation from naphazoline/ antazoline eye drops or flunisolide nasal spray, but none with the levocabastine preparations. Topical levocabastine may provide an interesting alternative in the treatment of allergic rhinoconjunctivitis.
|
Authors | M Bende, U Pipkorn |
Journal | Allergy
(Allergy)
Vol. 42
Issue 7
Pg. 512-5
(Oct 1987)
ISSN: 0105-4538 [Print] Denmark |
PMID | 2891316
(Publication Type: Clinical Trial, Comparative Study, Journal Article, Randomized Controlled Trial, Research Support, Non-U.S. Gov't)
|
Chemical References |
- Histamine H1 Antagonists
- Ophthalmic Solutions
- Piperidines
- levocabastine
|
Topics |
- Administration, Intranasal
- Adolescent
- Adult
- Conjunctivitis, Allergic
(drug therapy)
- Female
- Histamine H1 Antagonists
(therapeutic use)
- Humans
- Male
- Middle Aged
- Ophthalmic Solutions
- Piperidines
(administration & dosage, therapeutic use)
- Random Allocation
- Rhinitis, Allergic, Seasonal
(drug therapy)
|